Drugs and Devices

FDA approves Afrezza

On June 27, the U.S. Food and Drug Administration (FDA) approved Afrezza (insulin human) Inhalation Powder, a rapid-acting inhaled insulin to improve glycemic control in adults with diabetes mellitus. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares